These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials. EFSA GMO Panel Working Group on Animal Feeding Trials Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408 [TBL] [Abstract][Full Text] [Related]
7. Preclinical safety evaluation of recombinant adeno-associated virus 2 vector encoding human tumor necrosis factor receptor-immunoglobulin Fc fusion gene. Zhou X; Shen L; Liu L; Wang C; Qi W; Zhao A; Wu X; Li B Hum Vaccin Immunother; 2016 Mar; 12(3):732-9. PubMed ID: 26837862 [TBL] [Abstract][Full Text] [Related]
8. Evolution of a gene therapy clinical trial. From bench to bedside and back. Aguilar LK; Aguilar-Cordova E J Neurooncol; 2003 Dec; 65(3):307-15. PubMed ID: 14682380 [TBL] [Abstract][Full Text] [Related]
9. Viral vectors: a look back and ahead on gene transfer technology. Vannucci L; Lai M; Chiuppesi F; Ceccherini-Nelli L; Pistello M New Microbiol; 2013 Jan; 36(1):1-22. PubMed ID: 23435812 [TBL] [Abstract][Full Text] [Related]
10. Viral Vectors: The Road to Reducing Genotoxicity. David RM; Doherty AT Toxicol Sci; 2017 Feb; 155(2):315-325. PubMed ID: 27803388 [TBL] [Abstract][Full Text] [Related]
11. Not reinventing the wheel: applying the 3Rs concepts to viral vector gene therapy biodistribution studies. MacLachlan TK; McIntyre M; Mitrophanous K; Miskin J; Jolly DJ; Cavagnaro JA Hum Gene Ther Clin Dev; 2013 Mar; 24(1):1-4. PubMed ID: 23692377 [No Abstract] [Full Text] [Related]
12. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Serabian MA; Pilaro AM Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669 [TBL] [Abstract][Full Text] [Related]
13. Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. Smith KT; Shepherd AJ; Boyd JE; Lees GM Gene Ther; 1996 Mar; 3(3):190-200. PubMed ID: 8646549 [TBL] [Abstract][Full Text] [Related]
14. [Quality control of gene therapy products: approach of the French Agency for the Safety of Health Products]. Chenivesse X; Ridoux V; Tissier MH Med Sci (Paris); 2003 Apr; 19(4):481-8. PubMed ID: 12836223 [TBL] [Abstract][Full Text] [Related]
16. Preclinical biodistribution and safety study of reduced expression in immortalized cells/Dickkopf-3-encoding adenoviral vector for prostate cancer gene therapy. Sugimoto M; Watanabe M; Kaku H; Li SA; Noguchi H; Ueki H; Sakaguchi M; Huh NH; Nasu Y; Kumon H Oncol Rep; 2012 Nov; 28(5):1645-52. PubMed ID: 22941469 [TBL] [Abstract][Full Text] [Related]
18. Issues with biotechnology products in toxicologic pathology. Terrell TG; Green JD Toxicol Pathol; 1994; 22(2):187-93. PubMed ID: 7973366 [TBL] [Abstract][Full Text] [Related]
19. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. O'Neal WK; Zhou H; Morral N; Langston C; Parks RJ; Graham FL; Kochanek S; Beaudet AL Mol Med; 2000 Mar; 6(3):179-95. PubMed ID: 10965494 [TBL] [Abstract][Full Text] [Related]
20. Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals. Ru Q; Li W; Wang X; Zhang S; Chen L; Zhang Y; Ge Y; Zu Y; Liu Y; Zheng D Cancer Gene Ther; 2017 Jun; 24(6):251-258. PubMed ID: 28429751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]